Recce Pharmaceuticals provides new hope in fight against superbugs

–News Direct–

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham speaks with Proactive after welcoming positive clinical responses to a new gel formulation of its R327 drug candidate, covered by the Therapeutic Goods Administrations (TGA) Special Access Scheme (SAS). Anecdotal results from two patient case studies are a positive indicator of the gel formulations therapeutic potential, while results from an ex vivo burn wound study indicate the R327 gel had the greatest overall efficacy against a strand of antibiotic-resistant bacteria.

Recce is now advancing clinical trial applications to evaluate the R327 gels efficacy in common and complicated skin and soft tissue infections in the lab.

Graham said: Antibiotic resistance is globally recognised as one of the greatest threats to human health today.

To see Recce making a difference to patients in such great medical need before us, is another welcomed sign of new hope in the fight against drug-resistant superbugs.

We look forward to building upon these successes among the present and future clinical trials ahead.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

View source version on

Recce Pharmaceuticals Ltd

comtex tracking


Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Boston New Times  journalist was involved in the writing and production of this article.

Written by